KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Inventory (2018 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Change in Inventory for 8 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 1732.63% year-over-year to $13.9 million, compared with a TTM value of -$8.5 million through Dec 2025, up 37.65%, and an annual FY2025 reading of -$8.5 million, up 37.65% over the prior year.
  • Change in Inventory was $13.9 million for Q4 2025 at Alnylam Pharmaceuticals, up from -$5.0 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $19.0 million in Q4 2022 and bottomed at -$12.0 million in Q4 2023.
  • Average Change in Inventory over 5 years is $1.0 million, with a median of -$1.4 million recorded in 2022.
  • Peak annual rise in Change in Inventory hit 1732.63% in 2025, while the deepest fall reached 28150.0% in 2025.
  • Year by year, Change in Inventory stood at $10.8 million in 2021, then skyrocketed by 76.38% to $19.0 million in 2022, then tumbled by 163.18% to -$12.0 million in 2023, then skyrocketed by 92.92% to -$849000.0 in 2024, then surged by 1732.63% to $13.9 million in 2025.
  • Business Quant data shows Change in Inventory for ALNY at $13.9 million in Q4 2025, -$5.0 million in Q3 2025, and -$11.1 million in Q2 2025.